1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways

Kathy Vanderlaag, Yunpeng Su, Arthur E. Frankel, Henry Grage, Roger Smith, Shaheen Khan, Stephen Safe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes containing para-trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) groups are methylene-substituted diindolylmetyhanes (C-DIMs) that activate peroxisome proliferator-activated receptor γ (PPARγ) in estrogen receptor α-negative MDA-MB-231 and MDA-MB-453 breast cancer cells. C-DIMs inhibit breast cancer cell proliferation; however, inhibition of G0/G1 to S phase progression and cyclin D1 downregulation was observed in MDA-MB-231 but not MDA-MB-453 cells. Nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1), a transforming growth factor β-like peptide, was also induced by these compounds, and the response was dependent on cell-context dependent activation of kinase pathways. However, inhibition of cell growth, induction of NAG-1 and activation of kinases by C-DIMs were not inhibited by PPARγ antagonists. Despite the induction of NAG-1 and downregulation of the antiapoptotic protein survivin by C-DIMs in both MDA-MB-231 and MDA-MB-453 cells, apoptotic cell death was not observed. Nevertheless, the cytotoxicity of C-DIMs in vitro was complemented by inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as xenografts and treated with DIM-C-pPhC6H 5 (40 mg/kg/day). The growth inhibition of tumors derived from highly aggressive MDA-MB-231 cells suggests a potential role for the C-DIM compounds in the clinical treatment of ER-negative breast cancer.

Original languageEnglish (US)
Pages (from-to)273-283
Number of pages11
JournalBreast Cancer Research and Treatment
Volume109
Issue number2
DOIs
StatePublished - May 2008

Fingerprint

Methane
Estrogen Receptors
Breast Neoplasms
Peroxisome Proliferator-Activated Receptors
Nude Mice
Phosphotransferases
Down-Regulation
Growth
Cyclin D1
Transforming Growth Factors
Protein C
S Phase
Heterografts
Neoplasms
Cell Death
Anti-Inflammatory Agents
Cell Proliferation
Peptides
Pharmaceutical Preparations
Genes

Keywords

  • Breast cancer
  • C-DIMs
  • ER negative
  • Growth inhibition
  • PPARγ

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. / Vanderlaag, Kathy; Su, Yunpeng; Frankel, Arthur E.; Grage, Henry; Smith, Roger; Khan, Shaheen; Safe, Stephen.

In: Breast Cancer Research and Treatment, Vol. 109, No. 2, 05.2008, p. 273-283.

Research output: Contribution to journalArticle

@article{566f2478dd4f43b68d85cc609fa94a96,
title = "1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways",
abstract = "1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes containing para-trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) groups are methylene-substituted diindolylmetyhanes (C-DIMs) that activate peroxisome proliferator-activated receptor γ (PPARγ) in estrogen receptor α-negative MDA-MB-231 and MDA-MB-453 breast cancer cells. C-DIMs inhibit breast cancer cell proliferation; however, inhibition of G0/G1 to S phase progression and cyclin D1 downregulation was observed in MDA-MB-231 but not MDA-MB-453 cells. Nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1), a transforming growth factor β-like peptide, was also induced by these compounds, and the response was dependent on cell-context dependent activation of kinase pathways. However, inhibition of cell growth, induction of NAG-1 and activation of kinases by C-DIMs were not inhibited by PPARγ antagonists. Despite the induction of NAG-1 and downregulation of the antiapoptotic protein survivin by C-DIMs in both MDA-MB-231 and MDA-MB-453 cells, apoptotic cell death was not observed. Nevertheless, the cytotoxicity of C-DIMs in vitro was complemented by inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as xenografts and treated with DIM-C-pPhC6H 5 (40 mg/kg/day). The growth inhibition of tumors derived from highly aggressive MDA-MB-231 cells suggests a potential role for the C-DIM compounds in the clinical treatment of ER-negative breast cancer.",
keywords = "Breast cancer, C-DIMs, ER negative, Growth inhibition, PPARγ",
author = "Kathy Vanderlaag and Yunpeng Su and Frankel, {Arthur E.} and Henry Grage and Roger Smith and Shaheen Khan and Stephen Safe",
year = "2008",
month = "5",
doi = "10.1007/s10549-007-9648-y",
language = "English (US)",
volume = "109",
pages = "273--283",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways

AU - Vanderlaag, Kathy

AU - Su, Yunpeng

AU - Frankel, Arthur E.

AU - Grage, Henry

AU - Smith, Roger

AU - Khan, Shaheen

AU - Safe, Stephen

PY - 2008/5

Y1 - 2008/5

N2 - 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes containing para-trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) groups are methylene-substituted diindolylmetyhanes (C-DIMs) that activate peroxisome proliferator-activated receptor γ (PPARγ) in estrogen receptor α-negative MDA-MB-231 and MDA-MB-453 breast cancer cells. C-DIMs inhibit breast cancer cell proliferation; however, inhibition of G0/G1 to S phase progression and cyclin D1 downregulation was observed in MDA-MB-231 but not MDA-MB-453 cells. Nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1), a transforming growth factor β-like peptide, was also induced by these compounds, and the response was dependent on cell-context dependent activation of kinase pathways. However, inhibition of cell growth, induction of NAG-1 and activation of kinases by C-DIMs were not inhibited by PPARγ antagonists. Despite the induction of NAG-1 and downregulation of the antiapoptotic protein survivin by C-DIMs in both MDA-MB-231 and MDA-MB-453 cells, apoptotic cell death was not observed. Nevertheless, the cytotoxicity of C-DIMs in vitro was complemented by inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as xenografts and treated with DIM-C-pPhC6H 5 (40 mg/kg/day). The growth inhibition of tumors derived from highly aggressive MDA-MB-231 cells suggests a potential role for the C-DIM compounds in the clinical treatment of ER-negative breast cancer.

AB - 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes containing para-trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) groups are methylene-substituted diindolylmetyhanes (C-DIMs) that activate peroxisome proliferator-activated receptor γ (PPARγ) in estrogen receptor α-negative MDA-MB-231 and MDA-MB-453 breast cancer cells. C-DIMs inhibit breast cancer cell proliferation; however, inhibition of G0/G1 to S phase progression and cyclin D1 downregulation was observed in MDA-MB-231 but not MDA-MB-453 cells. Nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1), a transforming growth factor β-like peptide, was also induced by these compounds, and the response was dependent on cell-context dependent activation of kinase pathways. However, inhibition of cell growth, induction of NAG-1 and activation of kinases by C-DIMs were not inhibited by PPARγ antagonists. Despite the induction of NAG-1 and downregulation of the antiapoptotic protein survivin by C-DIMs in both MDA-MB-231 and MDA-MB-453 cells, apoptotic cell death was not observed. Nevertheless, the cytotoxicity of C-DIMs in vitro was complemented by inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as xenografts and treated with DIM-C-pPhC6H 5 (40 mg/kg/day). The growth inhibition of tumors derived from highly aggressive MDA-MB-231 cells suggests a potential role for the C-DIM compounds in the clinical treatment of ER-negative breast cancer.

KW - Breast cancer

KW - C-DIMs

KW - ER negative

KW - Growth inhibition

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=43149087555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149087555&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9648-y

DO - 10.1007/s10549-007-9648-y

M3 - Article

C2 - 17624585

AN - SCOPUS:43149087555

VL - 109

SP - 273

EP - 283

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -